Interpace Biosciences, Inc. (IDXG)

Interpace Biosciences, Inc. (IDXG) — VMCI valuation read

IDXG screens at VMCI 66/100, a 16-point gap above the Healthcare sector median (50). For a mid-cap Interpace Biosciences, Inc. share, that placement says the multi-pillar composite is cheaper or higher quality than the typical peer on a like-for-like basis.

IDXG has logged no Form 4 insider activity over the trailing 30 days. The tape reads neither bullish nor bearish on insider conviction. The next signal sits with the 10-Q schedule and the analyst calendar.

**Investor frame.** Value: IDXG trades at 26.0x earnings, 44% above the Healthcare median of 18.0x, while EV/EBITDA prints 9.0x against 12.0x for the Healthcare group. Quality: ROIC of 12.0% sits 2.0pp above the Healthcare median (10.0%), the cleanest like-for-like comparison on capital efficiency. Risk: net debt to EBITDA of 2.3x is the rate-sensitivity line to watch, which sets the rate-cycle exposure for Interpace Biosciences, Inc..

IDXG rose 1.2% over the trailing 7 days, with a -11.8% read on a 30-day basis.